A multidisciplinary transaction team from BDO AG Wirtschaftsprüfungsgesellschaft advised the Fagron Group on the acquisition of Euro OTC & Audor Pharma GmbH.
With the completed transaction, Fagron is not only taking over the formulation division, but is also strengthening its own market position as the number 2 in the industry in Germany. After Caelo and Fagron, the acquired Euro OTC was previously number 3 among suppliers of formulation substances in Germany. The integration of Euro OTC, which supplies around 2,500 pharmacies directly, should be completed within two years.
Fagron, an international market leader in the production of pharmaceutical formulations, was founded in Rotterdam in 1990 and expects to generate revenues of around EUR 850 million in the current year. The company employs around 3,600 people in a total of 37 countries worldwide, including Europe, North and South America, the Middle East, Africa, Asia and the Pacific region. Fagron's portfolio includes starting materials and formulation requirements as well as its own products, such as nutritional supplements or the production of sterile formulations in its own laboratories. The company has been listed on the stock exchange since 2007; the investment bank Goldman Sachs and the financial investor AOC are the largest shareholders.
BDO provided support for the transaction with a multidisciplinary transaction team from the Deal Advisory and Transaction Tax divisions under the leadership of partners Jan Odewald and Dr. Michael Brauer, with both a financial and a tax due diligence.